1. Pink Sheet

Pharma Industry On How To Tackle EU Regulatory & Reimbursement Barriers To Digital Therapeutics

 
• By Neena Brizmohun

When it comes to digital therapeutics in Europe, EFPIA says there is a lack of harmonization in the regulatory requirements, and only Belgium and Germany offer value assessment, reimbursement and funding pathways, with more intermittent offerings in countries like France and the UK.

Digital therapeutics deliver software driven, evidence-based therapeutic interventions to patients • Source: Shutterstock

Digital therapeutics (DTx) face unpredictable requirements or standards in Europe for much of the development and commercialization pathway, including marketing authorization, value assessment, reimbursement and pricing, the European Federation of Pharmaceutical Industries and Associations says in a report in which it recommends how to improve access to these technologies.

While there has been some progress in integrating DTx into market access and care pathways, only Belgium and Germany offer...

More from Europe

More from Geography

UK MHRA Helps Sponsors Prepare For ‘World’s First’ Decentralized Manufacturing Framework

 
• By Neena Brizmohun

The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.

Argentina Speeds Up Market Access Process

 
• By Francesca Bruce

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.